Imunon, Inc. Common Stock (IMNN) is a publicly traded Healthcare sector company. As of November 2, 2026, IMNN trades at $0.91 with a market cap of $23.31M and a P/E ratio of -0.16. IMNN moved -3.41% today. Year to date, IMNN is -76.96%; over the trailing twelve months it is -79.73%. Its 52-week range spans $0.81 to $41.22. Analyst consensus is strong buy with an average price target of $15.67. Rallies surfaces IMNN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Imunon agrees to sell ThermoDox rights to VoxelDox: Imunon agreed to sell its ThermoDox rights for an approximately 4.76% equity interest in VoxelDox, up to $16.5 million in milestone payments and tiered royalties of 3.5% to 6% of net sales if related products are approved. Closing depends on VoxelDox completing $2.5 million in financing for a Phase 1 glioblastoma trial; Imunon may appoint one VoxelDox director and one non-voting observer.
| Metric | Value |
|---|---|
| Price | $0.91 |
| Market Cap | $23.31M |
| P/E Ratio | -0.16 |
| EPS | $-6.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $41.22 |
| 52-Week Low | $0.81 |
| Volume | 3.45K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-14.50M |
| Gross Margin | 0.00% |
3 analysts cover IMNN: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.67.